Structure Therapeutics (GPCR) Expected to Announce Quarterly Earnings on Friday

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) is expected to be announcing its earnings results before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. On average, analysts expect Structure Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Structure Therapeutics Stock Down 10.9 %

Structure Therapeutics stock traded down $2.46 during mid-day trading on Monday, reaching $20.16. 859,499 shares of the company's stock were exchanged, compared to its average volume of 823,021. The company has a market cap of $1.15 billion, a P/E ratio of -27.24 and a beta of -2.37. Structure Therapeutics has a twelve month low of $19.61 and a twelve month high of $62.74. The company has a fifty day moving average of $25.98 and a 200-day moving average of $33.01.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on GPCR. William Blair initiated coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an "outperform" rating on the stock. JMP Securities reissued a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus began coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a "buy" rating and a $50.00 target price for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $81.29.

Remove Ads

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.